Healthcare / Medical DevicesNasdaqGM
$13.87
-0.23 (-1.63%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 25%
FCF escenarios
weak_data · normalized FCF $-22.9M · quality 64.0/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
30/100
D
Piotroski
6/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
20/100
SEC 0%
Sin guardar todavía.
Market Cap
$615M
P/E
N/A
•EV/EBITDA
N/A
•ROE
-10.6%
↓Gross Margin
79.6%
↑Debt/Equity
0.21
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2017–2025 · 8 años de histórico normalizado
Revenue CAGR
+19.6%
FCF CAGR
—
FCF margin
-4.5%
FCF / Net income
0.48x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $200.9M · net income $-18.9M · FCF $-9.1M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||||
| Revenue | $200.9M | $200.9M | $167.2M | $138.9M | $106.4M | $90.2M | $73.4M | $67.3M | $55.4M | $48.0M |
| Net Income | $-18.9M | $-18.9M | $-30.9M | $-43.3M | $-61.3M | $-56.6M | $-43.7M | $-38.4M | $-17.5M | $-23.0M |
| EBITDA | $-10.5M | $-10.5M | $-23.1M | $-34.4M | $-55.0M | $-49.6M | $-37.4M | $-35.2M | $-11.2M | $-16.3M |
| EPS | -0.44 | -0.44 | -0.75 | -1.13 | -1.79 | -1.71 | -1.50 | — | — | — |
| Gross Margin | 79.6% | 79.6% | 79.0% | 78.8% | 85.2% | 88.4% | 87.9% | 89.9% | 91.3% | 89.3% |
| Operating Margin | -11.1% | -11.1% | -21.1% | -33.8% | -56.0% | -57.3% | -52.6% | -53.5% | -21.6% | -36.2% |
| Net Margin | -9.4% | -9.4% | -18.5% | -31.2% | -57.6% | -62.8% | -59.5% | -57.1% | -31.5% | -48.0% |
| Balance Sheet | ||||||||||
| Debt/Equity | 0.21 | 0.21 | 0.22 | 0.23 | 0.40 | 0.26 | 0.23 | 0.55 | 0.43 | -0.30 |
| Current Ratio | 9.99 | 9.99 | — | — | — | — | — | — | — | — |
| Cash Flow | ||||||||||
| Free Cash Flow | $-9.1M | $-9.1M | $-22.9M | $-26.5M | $-51.2M | $-45.9M | $-33.2M | $-34.1M | $-15.5M | $-18.0M |
| Returns | ||||||||||
| ROE | -10.6% | -10.6% | -18.5% | -25.6% | -62.3% | -42.1% | -25.8% | -60.9% | -19.4% | 17.8% |
| Valuation | ||||||||||
| P/B | 3.36 | 3.36 | 3.54 | 4.72 | 4.42 | — | — | — | — | — |
| Growth & Yield | ||||||||||
| Revenue Growth | 20.2% | 20.2% | 20.4% | 30.5% | — | 22.8% | 9.0% | 21.5% | 15.4% | — |
| EPS Growth | 41.3% | 41.3% | 33.6% | 36.9% | — | -14.0% | — | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-26.6%
Start / end P/E
n/dx → n/dx
EPS bridge
-0.75 → -0.44
Residual
-26.6%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.